Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Trial details
- Registry ID
- NCT07007312
- Phase
- Phase 3
The FDA approved Ziftomenib (KO-539) on 13 Nov 2025.
Drug identity checked against registry records
Also recorded as KO-539
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLNCT07007312 | KURA | Phase 3 | Recruiting | 2031-11Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2025-11-13Day | Ziftomenib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA220305", "applicant_as_listed_by_fda": "KURA", "brand_names": ["KOMZIFTI"], "active_ingredients": ["ZIFTOMENIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20251113", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |